HSCRC Overview

Welcome to the HSCRC

The Maryland Health Services Cost Review Commission (HSCRC) is an independent state agency ensuring all Marylanders have access to high-value, affordable healthcare. We regulate hospital rates, advance health system transformation, and support the innovative AHEAD Model to improve care quality, health outcomes, and cost-efficiency. Learn More about the AHEAD Model.

Notices

** DUE TO ONGOING RENOVATIONS, MEMBERS OF THE PUBLIC MUST PARTICIPATE VIRTUALLY **

HSCRC July 2026 Commission Meeting – July 22, 2026

VIRTUAL ONLY VIA ZOOM

The Commission will begin in public session at 12:00pm via Zoom

for the purpose of, upon motion and approval, adjourning into closed session.

The open session will resume at 1:00pm

Topic: HSCRC July Commission Meeting

Time: July 22, 2026, 1:00 PM Eastern Time (US and Canada)

Join Zoom Meeting

Meeting ID: 410 764 2605
Passcode: 9Hm89B

NOTICE OF WRITTEN COMMENT PERIOD

Notice is hereby given that the public and interested parties are invited to submit written comments to the Commission on AHEAD Transition Funds.

Written comments on the questions outlined before should be sent to [email protected] on or before August 10, 2026.

How should AHEAD transition funds be allocated among the following options?

a) Funds should be allocated according to revenue by hospital as this is the simplest methodology.
b) Funds should be allocated in a way that favors smaller non-system hospitals as (a) these hospitals do not benefit from the economies of scale of larger systems and (b) many transition costs are fixed regardless of hospital size and therefore should not be allocated based on size. Under this approach Staff could set a per hospital amount or cap the size of the global budget eligible for allocation at a hospital or system level (e.g. systems of size greater than X are treated as size X).

c) Some amount of funding should be segregated and provided to a neutral service provider such as CRISP or MHA to procure shared technical support for all hospitals. This approach would prevent duplicative cost across hospitals and allow for the industry to leverage a common best-in-class solution for common needs but would add complexity to distributing and accessing the funding.

Are there specific approaches to any of items 1a to 1c the commenter would recommend?
What level of accountability should be required of hospitals to demonstrate the funding was being used responsibly and for the purposes it was intended? Options could range from a short report from management on the use of funds to detailed cost reporting with auditing of reported amounts. As required activities move along that continuum the level of accountability increases but so does the administrative burden on hospitals and Staff.

Stay Connected

Have questions or suggestions? We’re here to help. Contact Us

Cell and Gene Therapy Access Model

Maryland Medicaid is participating in CMS' Cell and Gene Therapy Access Model. Learn more.

IN MEMORY OF GRAHAM ATKINSON, LYNN GARRISON, AND RODNEY SPANGLER.